End­points Man­u­fac­tur­ing: Lon­za drops in­gre­di­ents biz in $4.7B sale; Touch­light's 'dog­gy­boneD­NA' looks to rewrite rules of ther­a­peu­tic DNA

In a CD­MO in­dus­try flush with cash from Covid-19, the rich keep get­ting rich­er — but that doesn’t mean the top dogs aren’t look­ing for op­por­tu­ni­ties to of­fload lag­gard busi­ness­es and rake in some cash. That’s ex­act­ly what Lon­za did in hiv­ing off its in­gre­di­ents unit — End­points Man­u­fac­tur­ing’s top sto­ry of the week.

On Mon­day, the near­ly 125-year-old Swiss gi­ant di­vest­ed its spe­cial­ty in­gre­di­ents busi­ness in a $4.7 bil­lion deal with Bain Cap­i­tal and Cin­ven, the UK pri­vate eq­ui­ty firm. The sale will see Bain and Cin­ven take over Lon­za’s 17 in­gre­di­ents sites around the world, which host some 2,800 work­ers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.